# YDJC

## Overview
The YDJC gene encodes the YdjC chitooligosaccharide deacetylase homolog, a protein that plays a significant role in cellular processes related to cancer progression, particularly in lung cancer. This protein is categorized as a deacetylase, which is involved in the modification of chitin-derived oligosaccharides. YDJC is implicated in the regulation of epithelial-mesenchymal transition (EMT), a critical process in cancer metastasis, through its interactions with proteins such as CDC16 and protein phosphatase 2A (PP2A). These interactions influence key signaling pathways, including the ERK2 pathway, which are essential for cancer cell migration and invasion. The clinical significance of YDJC is underscored by its association with poor prognosis in lung cancer patients, making it a potential target for therapeutic intervention (Kim2018YdjC; Kim2019YDJC).

## Clinical Significance
The YDJC gene, known as YdjC chitooligosaccharide deacetylase homolog, has been implicated in the progression of lung cancer. Alterations in YDJC expression levels are associated with poor prognosis in lung cancer patients. High expression of YDJC correlates with decreased overall survival and progression-free survival, particularly in stage 1 lung cancer patients, where it is linked to higher hazard ratios for poor outcomes (Kim2018YdjC). The gene's interaction with CDC16 is crucial, as it influences keratin 8 (K8) phosphorylation and reorganization, processes that are important for cancer cell migration and invasion (Kim2018YdjC).

The deacetylase activity of YDJC is essential for these effects, and mutations affecting this activity, such as the YDJC D13A mutation, can impact lung cancer cell behavior by altering keratin reorganization and ERK pathway activation (Kim2018YdjC). The study suggests that targeting YDJC or its interaction with CDC16 could be a potential therapeutic strategy for lung cancer, highlighting its clinical significance in cancer progression (Kim2018YdjC). These findings underscore the potential of YDJC as a target for anticancer drug development.

## Interactions
YDJC, a chitooligosaccharide deacetylase homolog, is involved in several protein interactions that influence epithelial-mesenchymal transition (EMT) in lung cancer cells. One significant interaction is with CDC16, a protein that binds to YDJC and suppresses its EMT-inducing effects. CDC16 achieves this by promoting the ubiquitination of YDJC, which in turn increases the expression of E-cadherin and decreases N-cadherin expression, markers associated with EMT (Kim2019YDJC). 

YDJC also interacts with protein phosphatase 2A (PP2A), which it downregulates through ubiquitination. This downregulation is crucial for the activation of ERK2, a kinase involved in promoting EMT and lung cancer progression (Kim2019YDJC). The interaction between YDJC and PP2A is modulated by CDC16, which can reverse the effects of YDJC by enhancing its ubiquitination, thereby increasing PP2A expression and suppressing EMT (Kim2019YDJC).

These interactions suggest that YDJC plays a pivotal role in the regulation of EMT through its interactions with CDC16 and PP2A, highlighting its potential as a target for therapeutic intervention in lung cancer (Kim2019YDJC).


## References


[1. (Kim2018YdjC) Eun Ji Kim, Mi Kyung Park, Hyun Jung Byun, Gyeoung Jin Kang, Lu Yu, Hyun Ji Kim, Jae Gal Shim, Ho Lee, and Chang Hoon Lee. Ydjc chitooligosaccharide deacetylase homolog induces keratin reorganization in lung cancer cells: involvement of interaction between ydjc and cdc16. Oncotarget, 9(33):22915–22928, May 2018. URL: http://dx.doi.org/10.18632/oncotarget.25145, doi:10.18632/oncotarget.25145. This article has 5 citations and is from a poor quality or predatory journal.](https://doi.org/10.18632/oncotarget.25145)

[2. (Kim2019YDJC) Eun Ji Kim, Mi Kyung Park, Gyeoung-Jin Kang, Hyun Jung Byun, Hyun Ji Kim, Lu Yu, Boram Kim, Hee-Sung Chae, Young-Won Chin, Jae Gal Shim, Ho Lee, and Chang Hoon Lee. Ydjc induces epithelial-mesenchymal transition via escaping from interaction with cdc16 through ubiquitination of pp2a. Journal of Oncology, 2019:1–15, August 2019. URL: http://dx.doi.org/10.1155/2019/3542537, doi:10.1155/2019/3542537. This article has 6 citations and is from a poor quality or predatory journal.](https://doi.org/10.1155/2019/3542537)